Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 38, Issue 9

Issues

Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses

Gérard Siest / Philippe Bertrand / Bernard Herbeth / Monique Vincent-Viry / Françoise Schiele / Catherine Sass / Sophie Visvikis
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.122

Abstract

Apolipoprotein (apo) E is an important circulating and tissue protein involved in cholesterol homeostasis and many other functions. The common polymorphism in the coding region of the gene, four polymorphisms in the promoter region, other additional single nucleotide polymorphisms, as well as several apo E variants have been identified. The common coding polymorphism strongly influences the lipid metabolism and the circulating concentration of apo E itself. This polymorphism is at the origin of the implication of apo E in cardiovascular and neurodegenerative diseases, but also of the relation of apo E with longevity. Probably due to its many metabolic and functional consequences, apo E polymorphism has been shown to influence the responses of patients to several drugs (fibrates, statins, hormone replacement therapy, anti-Alzheimer drugs) or environmental interventions (black tea, alcohol, diet). Apo E genotyping may be clinically helpful in defining the risk of patients and their responses to therapeutics. Finally, circulating apo E concentration appears to be altered in diseases and can be modulated by some of the drugs cited above. This parameter can thus also give interesting clinical information and could be a therapeutic target, providing it is validated. At the present time, we cannot exclude that apo E concentration may be the most prominent apo E parameter to be considered in health and disease, while apo E polymorphisms would represent only secondary parameters influencing apo E concentration.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 841–852, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.122.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Said El Shamieh, Christy Costanian, Rayan Kassir, Sophie V Siest, and Nisrine Bissar-Tadmouri
Personalized Medicine, 2018
[2]
Emad Ahmed and Ayman El-Menyar
Angiology, 2015, Volume 66, Number 5, Page 405
[3]
Daniela Scarabino, Elisabetta Broggio, Giuseppe Gambina, Carlotta Maida, Maria Rosa Gaudio, and Rosa Maria Corbo
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, Volume 171, Number 8, Page 1131
[4]
Tobias Mueller, Janett Fischer, Reinhard Gessner, Jonas Rosendahl, Stephan Böhm, Florian van Bömmel, Viola Knop, Christoph Sarrazin, Heiko Witt, Andreas Mas Marques, Peter Kovacs, Dorit Schleinitz, Michael Stumvoll, Matthias Blüher, Peter Bugert, Eckart Schott, and Thomas Berg
Liver International, 2016, Volume 36, Number 9, Page 1267
[5]
Alan Rembach, Tim M Ryan, Blaine R Roberts, James D Doecke, William J Wilson, Andrew D Watt, Kevin J Barnham, and Colin L Masters
Biomarkers in Medicine, 2013, Volume 7, Number 4, Page 641
[6]
Carmen Noelker, Harald Hampel, and Richard Dodel
Molecular Diagnosis & Therapy, 2011, Volume 15, Number 2, Page 83
[7]
Shuk-woon Ma, Iris F.F. Benzie, and Vincent T.F. Yeung
Translational Research, 2008, Volume 152, Number 3, Page 134
[8]
Alastair J.J. Wood, William E. Evans, and Howard L. McLeod
New England Journal of Medicine, 2003, Volume 348, Number 6, Page 538
[9]
Gérard Siest, Jean-Brice Marteau, Sandy Maumus, Hind Berrahmoune, Elise Jeannesson, Anastasia Samara, Anne-Marie Batt, and Sophie Visvikis-Siest
European Journal of Pharmacology, 2005, Volume 527, Number 1-3, Page 1
[10]
Alexander D Dergunov, Aline Hoy, Elizaveta A Smirnova, Sophie Visvikis, and Gerard Siest
The International Journal of Biochemistry & Cell Biology, 2003, Volume 35, Number 4, Page 530
[11]
Maura Poli, Luisa Benerini Gatta, Roberto Dominici, Carlo Lovati, Claudio Mariani, Alberto Albertini, and Dario Finazzi
Clinical Chemistry and Laboratory Medicine (CCLM), 2005, Volume 43, Number 5
[12]
Lars Ulrik Gerdes
Clinical Chemistry and Laboratory Medicine, 2003, Volume 41, Number 5
[13]
Eliane Albuisson, Sandy Maumus, Ndeye-Coumba Ndiaye, Bérangère Marie, Nicolas Jay, François Kohler, Gérard Siest, and Sophie Visvikis-Siest
Clinical Chemistry and Laboratory Medicine, 2008, Volume 46, Number 1
[14]
Anca Sima, Alexandru Iordan, and Camelia Stancu
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 9
[16]
Gérard Siest, Luc Ferrari, Marie-José Accaoui, Anne-Marie Batt, and Sophie Visvikis
Clinical Chemistry and Laboratory Medicine, 2003, Volume 41, Number 4
[17]
G Siest, E Jeannesson, H Berrahmoune, S Maumus, J-B Marteau, S Mohr, and S Visvikis
Pharmacogenomics, 2004, Volume 5, Number 7, Page 779
[18]
Helen F Galley, Amr Mahdy, and Damon A Lowes
Pharmacogenomics, 2005, Volume 6, Number 8, Page 849
[19]
[20]
Tharani Sabaretnam, Jennifer O’Reilly, Leonard Kritharides, and David G. Le Couteur
AGE, 2010, Volume 32, Number 1, Page 69
[21]
Philine Schneider, Harald Hampel, and Katharina Buerger
CNS Neuroscience & Therapeutics, 2009, Volume 15, Number 4, Page 358
[22]
Loes E. Visser, Paul H. Trienekens, Peter AGM De Smet, Arnold G. Vulto, Albert Hofman, Cornelia M. van Duijn, and Bruno HCh Stricker
Pharmacogenetics and Genomics, 2005, Volume 15, Number 2, Page 69
[23]
Minhaz Uddin Ahmed, Koutarou Idegami, Miyuki Chikae, Kagan Kerman, Piyasak Chaumpluk, Shohei Yamamura, and Eiichi Tamiya
The Analyst, 2007, Volume 132, Number 5, Page 431
[24]
Sonia Gueguen, Bernard Herbeth, Pascal Pirollet, Fran??ois Paille, G??rard Siest, and Sophie Visvikis
Alcoholism: Clinical and Experimental Research, 2002, Volume 26, Number 4, Page 501
[25]
Sonia Gueguen, Bernard Herbeth, Pascal Pirollet, Francois Paille, Gerard Siest, and Sophie Visvikis
Alcoholism: Clinical and Experimental Research, 2002, Volume 26, Number 4, Page 501
[26]
V. A. Sukhanov, I. D. Ionov, and L. A. Piruzyan
Human Physiology, 2005, Volume 31, Number 4, Page 472
[28]
Christian Lavedan, Gunther Birznieks, Marlene Dressman, Karen McCullough, Rebecca Paczkowski, Rosa Torres, Curt Wolfgang, and Mihael Polymeropoulos
Drug Development Research, 2004, Volume 62, Number 4, Page 371
[29]
G�rard Siest, Mohamed Zaiou, and Sophie Visvikis
Drug Development Research, 2002, Volume 56, Number 2, Page 95

Comments (0)

Please log in or register to comment.
Log in